Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients

FHS
July 30, 2024
8:50 am

A randomized clinical trial (RCT) to investigate the effectiveness of curcumin in lowering depression among obese individuals with diabetes mellitus type 2 (T2DM).

Novo Nordisk budgets $4.1B for new US manufacturing site as it abandons plans for Irish build

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 25, 2024

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Psychedelic Invest

The multi-centre, quadruply-masked Phase IIb study aims to assess the efficacy and safety of different doses of BPL-003 in patients with Treatment Resistant Depression (TRD).

October 25, 2023

Key plasma proteins signal critical periods in brain aging

Researchers identified 13 plasma proteins linked to brain aging, uncovering dynamic patterns and biomarkers for early intervention in aging-related brain health.

December 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.